AU2012904839A0 - Phage therapy for the treatment of MRSA infections - Google Patents

Phage therapy for the treatment of MRSA infections

Info

Publication number
AU2012904839A0
AU2012904839A0 AU2012904839A AU2012904839A AU2012904839A0 AU 2012904839 A0 AU2012904839 A0 AU 2012904839A0 AU 2012904839 A AU2012904839 A AU 2012904839A AU 2012904839 A AU2012904839 A AU 2012904839A AU 2012904839 A0 AU2012904839 A0 AU 2012904839A0
Authority
AU
Australia
Prior art keywords
treatment
phage therapy
mrsa infections
mrsa
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012904839A
Inventor
Anthony M. Smithyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Special Phage Holdings Pty Ltd
Original Assignee
Special Phage Holdings Pty Ltd
Filing date
Publication date
Application filed by Special Phage Holdings Pty Ltd filed Critical Special Phage Holdings Pty Ltd
Publication of AU2012904839A0 publication Critical patent/AU2012904839A0/en
Abandoned legal-status Critical Current

Links

AU2012904839A 2012-11-06 Phage therapy for the treatment of MRSA infections Abandoned AU2012904839A0 (en)

Publications (1)

Publication Number Publication Date
AU2012904839A0 true AU2012904839A0 (en) 2012-11-22

Family

ID=

Similar Documents

Publication Publication Date Title
HK1211589A1 (en) Compounds for the treatment of paramoxyvirus viral infections
HK1216421A1 (en) Therapeutic compounds for the treatment of viral infections
IL233499B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IL240765A0 (en) Macrocyclic deaza-purinones for the treatment of viral infections
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
HK1210018A1 (en) Tailored liposomes for the treatment of bacterial infections
IL245085B (en) Phage therapy of pseudomonas infections
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
EP3062790A4 (en) Pharmaceutical combinations for the treatment of cancer
EP2991650A4 (en) Methods for the treatment of cancer
ZA201306342B (en) The treatment of viral infections
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
EP3040071A4 (en) Therapeutic agent for dyslipidemia
EP3016948B8 (en) 2-acylaminothiazoles for the treatment of cancer
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
AU2012904839A0 (en) Phage therapy for the treatment of MRSA infections
ZA201308806B (en) Liposomal vancomycin for the treatment of mrsa infections
EP3049075A4 (en) Laquinimod combination therapy for treatment of multiple sclerosis
AU2013904483A0 (en) Process for the treatment of kaolin
PT2861214T (en) Tailored liposomes for the treatment of bacterial infections
AU2014901885A0 (en) Compounds for the treatment of antibacterial infections
AU2013904239A0 (en) Pharmaceutical combinations for the treatment of cancer
GB201212715D0 (en) Treatment of fungal infections
AU2012900285A0 (en) Methods of treatment or prophylaxis
AU2012900057A0 (en) Methods of treatment or prophylaxis